Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Rating Lowered to Hold at Deutsche Bank

Deutsche Bank downgraded shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) from a buy rating to a hold rating in a research report released on Thursday morning, The Fly reports.

Shares of OTCMKTS:BIOVF opened at $20.35 on Thursday.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.

Further Reading: Why is cost of goods sold important?

The Fly

Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.